These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 35429905)
1. BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults. Verma D; Kumar R; Ali MS; Singh J; Arora M; Singh I; Kumari S; Bakhshi S; Sharma A; Palanichamy JK; Tanwar P; Singh AR; Chopra A Blood Cells Mol Dis; 2022 Jul; 95():102662. PubMed ID: 35429905 [TBL] [Abstract][Full Text] [Related]
2. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022 [TBL] [Abstract][Full Text] [Related]
3. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia. Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607 [TBL] [Abstract][Full Text] [Related]
5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041 [TBL] [Abstract][Full Text] [Related]
6. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058 [TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype. Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229 [TBL] [Abstract][Full Text] [Related]
9. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H; Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978 [TBL] [Abstract][Full Text] [Related]
10. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102 [TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432 [TBL] [Abstract][Full Text] [Related]
12. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD; Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853 [TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874 [TBL] [Abstract][Full Text] [Related]
14. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499 [TBL] [Abstract][Full Text] [Related]
15. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446 [TBL] [Abstract][Full Text] [Related]
17. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798 [TBL] [Abstract][Full Text] [Related]
18. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128 [TBL] [Abstract][Full Text] [Related]
19. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD; J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018 [TBL] [Abstract][Full Text] [Related]
20. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India. Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]